Prognostic role of platelet to lymphocyte ratio in esophageal cancer: A meta-analysis

Qing-Tao Zhao, Xiao-Peng Zhang, Hua Zhang and Guo-Chen Duan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:112085-112093. https://doi.org/10.18632/oncotarget.22557

Metrics: PDF 1749 views  |   HTML 1802 views  |   ?  


Qing-Tao Zhao1,*, Xiao-Peng Zhang1,*, Hua Zhang1,* and Guo-Chen Duan1

1Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang 050051, Hebei, PR China

*These authors have contributed equally to this work

Correspondence to:

Guo-Chen Duan, email: [email protected]

Keywords: platelet to lymphocyte ratio; esophageal cancer; prognosis; meta-analysis

Received: June 06, 2017    Accepted: October 28, 2017    Published: November 20, 2017


Purpose: The prognostic role of inflammation index like platelet to lymphocyte ratio (PLR) in esophageal cancer remains controversial. We evaluated the prognostic significance of PLR in esophageal cancer patients.

Methods: We searched databases to identify relevant literatures. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. A meta-analysis was performed to evaluate the prognostic value of PLR in patients with esophageal cancer.

Results: A total of 6,699 patients from 16 studies (17 cohorts) were finally enrolled in the meta-analysis. The results demonstrate that the elevated PLR predicted poorer overall survival (OS) (HR: 1.389, 95% CI: 1.161-1.663) and disease-free survival (DFS) (HR: 1.404, 95% CI: 1.169-1.687) and cancer-specific survival (CSS) (HR: 1.686, 95% CI: 1.146-2.480) in patients with esophageal cancer. Subgroup analysis revealed that the elevated PLR was also associated with poor OS in esophageal cancer treated by surgery (HR: 1.492, 95%CI: 1.149-1.938, P<0.05) and mixed treatment (HR: 1.222, 95%CI: 1.009-1.479, P<0.05). In addition, PLR Cut-off value≤160 (HR: 1.484, 95%CI: 1.088-2.024, P<0.05) and PLR Cut-off value>160 (HR: 1.391, 95%CI: 1.161-1.666, P<0.05).

Conclusion: This meta-analysis result suggested that PLR might be a significant predicative biomarker of poor prognosis for esophageal cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22557